arrow
S

Suman Paul

Howard Hughes Medical Institute
H指数:20
被引数:2,024

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Hodgkin Lymphoma, Version 1.2026

霍奇金淋巴瘤,版本1.2026

2026-02-011
PRE
C-C motif chemokine receptor-like 2 promotes the interferon-γ signaling response in myeloid neoplasms with erythroid differentiation and mutated TP53

Naji, N.S.; Pasca, S.; Chatzilygeroudi, T.; Toledano-Sanz, P.; Rimando, J.; An, Y.; Hemani, Y.; Perkins, B.; Zeng, X.; Talbot, C.; 等. C-C基序趋化因子受体样2促进具有红系分化和TP53突变髓系肿瘤的干扰素-γ信号反应。Haematologica, 2025. [Google Scholar] [CrossRef]

2026-02-013
OA
Bispecific antibodies and CAR T cells targeting a TP53 mutation-associated neoantigen show discordant affinity requirements

双特异性抗体和靶向TP53突变相关新抗原的CAR T细胞显示出不同的亲和力需求

2026-01-160
OA
Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy
2025-11-011
OA
CCRL2 As a Novel Target in Acute Erythroid Leukemia

CCRL2 作为急性红系白血病的全新靶点

BLOOD
IF23.1
2024-11-050
PRE
Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densities
2024-07-101
PRE
Cancer therapy with antibodies

用抗体治疗癌症

2024-05-1314
PRE
TRBC1-targeting antibody–drug conjugates for the treatment of T cell cancers

用于治疗T细胞癌症的TRBC1-targeting抗体-药物结合物

Nature
IF48.5
2024-03-270
PRE
Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen

疏水相互作用主导了KRAS G12V新抗原的识别

2023-08-218
OAAI
Hybrid TCR-CAR design surpasses conventional CARs and patient-derived TCRs in targeting an ultra-low-density neoantigen
2023-04-140
PRE
Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide for Peripheral T Cell Lymphoma: The Importance of Graft Source

异基因血液或骨髓移植与移植后环磷酰胺治疗外周T细胞淋巴瘤: 移植物来源的重要性

2023-04-018
OAAI
Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens

靶向HLA限制性新抗原的嵌合抗原受体的结构工程

2021-09-0625
OAAI